The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Alliance A022106: A phase II/III trial of NABPLAGEM vs nab-paclitaxel/gemcitabine as second-line treatment for BRCA1/2 or PALB2 mutant metastatic pancreatic ductal adenocarcinoma (PLATINUM).
 
Erica S Tsang
Honoraria - AstraZeneca; Guardant Health; Incyte
Research Funding - Amgen; AstraZeneca; Roche/Genentech
 
Qian Shi
Honoraria - Chugai Pharma
Consulting or Advisory Role - Hoosier Cancer Research Network; Kronos Bio; Mirati Therapeutics; Regeneron; Yiviva
Research Funding - BMS (Inst); Celgene (Inst); Janssen (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
Kenneth P. Olive
No Relationships to Disclose
 
Eric Andrew Collisson
Stock and Other Ownership Interests - BloodQ; Clara Health; Guardant Health; HDT Bio; Hint Health; IHP Therapeutics; One Medical; Tatara Therapeutics; Valar Labs
Research Funding - AstraZeneca (Inst); Loxo/Bayer (Inst); Merck KGaA (Inst); Pfizer (Inst)
 
Jesse G. Dixon
Consulting or Advisory Role - ARTIDIS
 
Mike Cusnir
Speakers' Bureau - Guardant Health; Sirtex Medical
 
Rafael Winograd
No Relationships to Disclose
 
Gregory P. Botta
Honoraria - Natera
Consulting or Advisory Role - Natera
Speakers' Bureau - Natera
 
Raymond Couric Wadlow
Honoraria - AstraZeneca; Oncocyte; Pfizer; Seagen; Taiho Pharmaceutical
Consulting or Advisory Role - Exact Sciences; Johnson & Johnson (I)
Travel, Accommodations, Expenses - Exact Sciences
 
Ardaman Shergill
Honoraria - ASCO; Cholangiocarcinoma Foundation; cholangiocarcinoma summit; Colon Cancer Alliance; Curio Science; oklahoma society of clinical oncology; OncLive/MJH Life Sciences; saint joseph hospital Chicago
Consulting or Advisory Role - Catalyst Pharmaceuticals; Guardant Health; KLJ Associates; Pfizer; Pfizer; Triptych Health Partners
Research Funding - Astellas Pharma (Inst); BMS (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Gossamer Bio (Inst); Gritstone Bio (Inst); Hutchison MediPharma (Inst); Macrogenics (Inst); Merck (Inst); Oncologie (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TP Therapeutics (Inst); verastem (Inst)
Travel, Accommodations, Expenses - colon cancer alliance; Takeda
 
Jeffrey A. Meyerhardt
Research Funding - Boston Biomedical (Inst)
 
Eileen M. O'Reilly
Consulting or Advisory Role - Abbvie (I); AstraZeneca; Autem Medical (I); Berry Genomics (I); BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Eisai (I); Exelixis (I); Genentech/Roche (I); Ipsen; J-Pharma (I); Merck; Merus; Novartis; QED Therapeutics (I); SERVIER (I); Tempus; Vector Health (I); Yiviva (I)
Research Funding - Agenus (Inst); Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Bristol Myers Squibb (Inst); Digestive Care (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Helsinn Healthcare (Inst); Parker Institute for Cancer Immunotherapy (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Yiviva (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma
 
Andrew H. Ko
Honoraria - Medscape; MJH Life Sciences; Research to Practice
Consulting or Advisory Role - AADi; Arcus Biosciences; Eisai; FibroGen; Genentech; GRAIL; Merus; Roche/Genentech
Research Funding - AbGenomics International (Inst); Apexigen (Inst); Astellas Pharma (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CrystalGenomics (Inst); Genentech/Roche (Inst); Leap Therapeutics (Inst); Merck (Inst); Verastem (Inst)